Improved survival using specialized multidisciplinary board in sarcoma patients
Paper by Florence Duffaud indexed on Europe PMC as PubMed record 29117335, in Annals of Oncology (2017), one of the most cited records naming an author with this name at Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille.
Overview
Background: Sarcomas are rare but aggressive diseases. Specialized multidisciplinary management is not implemented for all patients in most countries. We investigated the impact of a multidisciplinary tumor board (MDTB) presentation before treatment in a nationwide study over 5 years.
Patients and methods: NETSARC (netsarc.org) is a network of 26 reference sarcoma centers with specialized MDTB, funded by the French National Cancer Institute to improve the outcome of sarcoma patients. Since 2010, presentation to an MDTB and second pathological review are mandatory for sarcoma patients in France. Patients' characteristics and follow-up are collected in a database regularly monitored and updated. The management and survival of patients presented to these MDTB before versus after initial treatment were analyzed.
Results: Out of the 12 528 patients aged ≥15 years, with a first diagnosis of soft tissue and visceral sarcoma obtained between 1 January 2010 and 31 December 2014, 5281 (42.2%) and 7247 (57.8%) were presented to the MDTB before and after the initiation of treatment, respectively. The former group had generally worse prognostic characteristics. Presentation to a MDTB before treatment was associated with a better compliance to clinical practice guidelines, for example, biopsy before surgery, imaging, quality of initial surgery, and less reoperations (all P < 0.001). Local relapse-free survival and relapse-free survival were significantly better in patients presented to a MDTB before initiation of treatment, both in univariate and multivariate analysis.
Conclusion: The compliance to clinical practice guidelines and relapse-free survival of sarcoma patients are significantly better when the initial treatment is guided by a pre-therapeutic specialized MDTB.
Indexed on Europe PMC as PubMed record 29117335 (DOI 10.1093/annonc/mdx484). Its author list gives "Duffaud F" with the affiliation "Department of Medical Oncology, La Timone University Hospital, Marseille", which names Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille; that is how the record was matched to Florence Duffaud, and no figure has been checked by an editor.
One of the most cited papers Europe PMC returns for Florence Duffaud at Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille, so it is a natural starting point for reading their work. The record was linked automatically from the author list and affiliation; read the abstract above and the paper itself before relying on any figure.
- Matched to the person by surname, initials and an affiliation string naming the institution on the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.
- Two authors sharing a surname, initials and institution cannot be told apart by this method; the person's profile links are the place to confirm authorship.